Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
PMID: 32165206

Abstract

INTRODUCTION: Histologic subtypes of malignant pleural mesothelioma are a major prognostic indicator and decision denominator for all therapeutic strategies. In an ambiguous case, a rare transitional mesothelioma (TM) pattern may be diagnosed by pathologists either as epithelioid mesothelioma (EM), biphasic mesothelioma (BM), or sarcomatoid mesothelioma (SM). This study aimed to better characterize the TM subtype from a histological, immunohistochemical, and molecular standpoint. Deep learning of pathologic slides was applied to this cohort.

Authors

  • Francoise Galateau Salle
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France. Electronic address: francoise.galateau@lyon.unicancer.fr.
  • Nolwenn Le Stang
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Franck Tirode
    University Claude Bernard Lyon, INSERM, CNRS, Research Cancer Center of Lyon, Centre Léon Bérard, Lyon, France.
  • Pierre Courtiol
    OWKIN Paris, France.
  • Andrew G Nicholson
    Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Ming-Sound Tsao
    University Health Network-Princess Margaret Cancer Centre and Toronto General Hospital, Toronto, Ontario, Canada.
  • Henry D Tazelaar
    Mayo Clinic, Scottsdale, Arizona.
  • Andrew Churg
    Columbia University and Department of Pathology Vancouver, Canada.
  • Sanja Dacic
    FISH and Developmental Laboratory at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Victor Roggli
    Duke University Medical Center, Department of Pathology, Durham, North Carolina.
  • Daniel Pissaloux
    Department of BioPathology-FISH Laboratory, Centre Leon Berard Lyon, France.
  • Charles Maussion
    OWKIN Paris, France.
  • Matahi Moarii
    OWKIN Paris, France.
  • Mary Beth Beasley
    Mount-Sinai Medical Center, Department of Pathology, New York, New York.
  • Hugues Begueret
    CHU Bordeaux, Haut Leveque Hospital, Department of Pathology, Bordeaux, France.
  • David B Chapel
    University of Chicago, Department of Pathology, Chicago, Illinois.
  • Marie Christine Copin
    University. Lille-CHU, Department of Pathology, Lille, France.
  • Allen R Gibbs
    University of Wales, Department of Cellular Pathology, Cardiff, United Kingdom.
  • Sonja Klebe
    Department of Anatomical Pathology, Flinders University, Adelaide, Australia.
  • Sylvie Lantuejoul
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Kazuki Nabeshima
    Department of Pathology, Fukuoka University School of Medicine and Hospital, Fukuoka, Japan.
  • Jean-Michel Vignaud
    CHU Nancy, INSERM, University of Lorraine, Lorraine, France.
  • Richard Attanoos
    University of Wales, Department of Cellular Pathology, Cardiff, United Kingdom.
  • Luka Brcic
    Department of Pathology, Graz, Austria.
  • Frederique Capron
    CHU Pitié Salpétrière Paris, Department of Pathology, Paris, France.
  • Lucian R Chirieac
    Brigham and Women's Hospital, Boston, Massachusetts.
  • Francesca Damiola
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Ruth Sequeiros
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.
  • Aurélie Cazes
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Bichat Department of Pathology, University Paris VII, Paris, France.
  • Diane Damotte
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Cochin-Hotel Dieu, Department of Pathology, Paris, France.
  • Armelle Foulet
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CH Le Mans, Department of Pathology, Pays de la Loire, France.
  • Sophie Giusiano-Courcambeck
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Hospital Nord, Marseille, University Aix-Marseille, Marseille, France.
  • Kenzo Hiroshima
    Tokyo Women's Medical University, Department of Pathology, Tokyo, Japan.
  • Véronique Hofman
    Laboratoire de pathologie clinique et expérimentale/biobanque (BB 0033-00025), Fédération hospitalo-universitaire OncoAge, CHU de Nice, université Côte-d'Azur, 30, voie Romaine, 06000 Nice, France; Équipe 4, CNRS UMR7284, Inserm U1081, faculté de médecine, institut de recherche sur le cancer et le vieillissement de Nice (Ircan), 28, avenue de Valombrose, 06107 Nice, France.
  • Aliya N Husain
    University of Chicago, Department of Pathology, Chicago, Illinois.
  • Keith Kerr
    Aberdeen Royal Infirmary, Department of Pathology, Aberdeen, Scotland.
  • Alberto Marchevsky
    Scotland Cedars-Sinai Medical Center, Department of Pathology, Los Angeles, California.
  • Severine Paindavoine
    University Claude Bernard Lyon, INSERM, CNRS, Research Cancer Center of Lyon, Centre Léon Bérard, Lyon, France.
  • Jean Michel Picquenot
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Department of Pathology, Henri Becquerel Centre, Rouen, France.
  • Isabelle Rouquette
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; IUCT-Oncopôle, Department of Pathology, Toulouse, France.
  • Christine Sagan
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Nantes, INSERM, Thorax Institute, Hôpital Laënnec CHU Nantes, Nantes, France.
  • Jennifer Sauter
    Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York.
  • Francoise Thivolet
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Hospices Civils, East Hospital Group, Department of Pathology, Lyon, France.
  • Marie Brevet
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Hospices Civils, East Hospital Group, Department of Pathology, Lyon, France.
  • Philippe Rouvier
    CHU Pitié Salpétrière Paris, Department of Pathology, Paris, France.
  • William D Travis
    Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York.
  • Gaetane Planchard
    MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Department of Pathology, CHU Caen, Caen, France.
  • Birgit Weynand
    UZ Leuven, Department of Pathology, Leuven, Belgium.
  • Thomas Clozel
    OWKIN Paris, France.
  • Gilles Wainrib
    Ecole Normale Supérieure, Département d'Informatique, équipe DATA, Paris, France.
  • Lynnette Fernandez-Cuesta
    Genetic Cancer Susceptibility Group International Agency for Research on Cancer World Health Organization, Lyon, France.
  • Jean-Claude Pairon
    INSERM, UPEC, Faculty of Medicine and CHI Creteil, Professional Pathologies and Environment Department, IST-PE, Creteil, France.
  • Valerie Rusch
    Memorial Sloan Kettering Cancer Center, Department of Thoracic Surgery, New York, New York.
  • Nicolas Girard
    Department of Thoracic Oncology Institute Curie Paris, France and European Reference Network EURACAN, Centre Leon Berard, France.

Keywords

External Resources

Popular Topics
Recent Journals